Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the...

Descripción completa

Detalles Bibliográficos
Publicado en:AIDS & Behavior Vol. 29; no. 10; pp. 3026 - 3036
Autores principales: Schaack, Alice K., Allamong, Maxwell B., Hung, Frances, Barfield, Richard T., Wilson, Sarah M., Watkins, Tina, Link, Katherine, McKellar, Mehri S.
Formato: research tables/charts Journal Article
Publicado: Springer Nature Oct2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188353287&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188353287
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10907165
        G1T
      jtl: AIDS & Behavior
      issn: 10907165
      maglogo: N
    pubinfo:
      dt: Oct2025
      vid: 29
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        188353287
        185961677
        188353287
        188353287
        10.1007/s10461-025-04749-0
        188353287
      ppf: 3026
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.
      aug:
        au:
          Schaack, Alice K.
          Allamong, Maxwell B.
          Hung, Frances
          Barfield, Richard T.
          Wilson, Sarah M.
          Watkins, Tina
          Link, Katherine
          McKellar, Mehri S.
        affil: https://ror.org/00py81415 Duke School of Medicine, Duke University, Durham, NC, USA
      sug:
        subj:
          Pre-Exposure Prophylaxis Evaluation
          HIV Infections Prevention and Control
          Patient Attitudes Evaluation
          Attitude to Medical Treatment Evaluation
          Delayed-Action Preparations
          Injections
          Administration, Oral
          HIV Infections Risk Factors
          Risk Assessment
          Health Services Accessibility
          Stigma
          North Carolina
          Funding Source
          Human
          Male
          Female
          Adult
          Middle Age
          Aged
          Cross Sectional Studies
          Convenience Sample
          Pre-Exposure Prophylaxis Adverse Effects
          Pre-Exposure Prophylaxis Economics
          Health Care Costs
          Multivariate Analysis
          Multiple Logistic Regression
          Chi Square Test
          Data Analysis Software
          Descriptive Statistics
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the U.S. South. Eligible participants were 18 + and had previously taken or been prescribed oral or LAI PrEP. They were asked their opinions on PrEP, barriers to access, perceived HIV risk, and PrEP stigma. Between January and April 2024, 123 people participated. Twenty-two (17.9%) used LAI PrEP, 80 (65.0%) oral PrEP, and 21 (17.1%) were not currently using PrEP. Most participants identified as men (87.8%), and mean age was 38.6 (range 19–78). Participants were 52.8% White, 27.6% Black, and 14.6% Latinx. 56.1% preferred injection versus daily oral pill. Common concerns about PrEP included side effects (n = 48), cost of medication (n = 21), and cost of clinic visits/tests (n = 21). Of those taking oral PrEP, 56.3% reported remaining on oral because LAI was not offered to them and/or they were not aware of it. Perceived HIV risk scores were on average higher for those not currently taking PrEP (not on = 26.8, SD = 6.54; LAI = 22.3, SD = 6.45; oral = 24.2, SD = 6.13). Overall, participants had low to moderate PrEP stigma scores. Despite majority preference for LAI PrEP, patients are frequently unaware of or not offered LAI. Common concerns about PrEP include side effects and costs. These data demonstrate the importance of improving LAI PrEP awareness and accessibility of choice.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N